Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A

  • Cocrystal Pharma Inc COCP announced that CC-42344 demonstrated a favorable safety profile in the single-ascending and multiple-ascending dose portions of the ongoing Phase 1 study. 
  • CC-42344 is a broad-spectrum oral antiviral for pandemic and seasonal influenza A.
  • The randomized, double-controlled, dose-escalating Phase 1 study in Australia was designed to assess the safety, tolerability, and pharmacokinetics (PK) of orally administered CC-42344 in healthy adults. 
  • Related: Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate.
  • In July 2022, Cocrystal reported that PK data from the single-ascending dose portion of the study supported once-daily dosing. 
  • In October 2022, enrollment in the multiple-ascending dose portion of the trial was completed.
  • The company plans to present topline study results at the upcoming World Antiviral Congress on December 1 and submit an application with the United Kingdom Medicines and Healthcare Products Regulatory Agency to conduct a Phase 2a human challenge study in early 2023. 
  • Subject to regulatory agency clearance, the Phase 2a study is expected to be initiated in the second half of 2023.
  • Price Action: COCP shares are up 2.49% at $3.07 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!